Best Life Sciences Companies in Glasgow, United Kingdom
The 37 best Life Sciences companies in Glasgow, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Mironid.
Our analysis of 62 Life Sciences companies
$9.8b in tracked funding; 75% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2026.
Ranked: Best Life Sciences companies in Glasgow
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Mironid Molecules to modulate the activity of phosphodiesterase 4 (PDE4) enzymes to treat inflammatory disease and… | $45M | 36 mo ago | 12 12 → 16 (+33%) | Neil Wilkie CEO | Series A | 32 patents Design and synthesis of small‑molecule PDE4 activators for therapeutic applications | — |
| 2 | Chemify Developer of a platform for digitizing chemistry and chemical discovery 64Growth top 20%Funding top 26%AI top 30%Tech top 40% All 11 signals ▾Growthtop 20% Fundingtop 26% AItop 30% Techtop 40% Talentbottom 49% Marketbottom 44% Globalbottom 42% Moatbottom 42% Patentsbottom 40% Innovationbottom 39% Newsbottom 17% Growth: Web rank 50,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo Funding: Raised $43.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $43M | 7 mo ago | 40 | Lee Cronin Founder & CEO | Series B | 2 patents Enzyme‑based catalytic processing platforms and networked bioreaction systems | — |
| 3 | M Squared Developer of light-sheet microscopy systems for multiple business verticals | $31M | 69 mo ago | 110 | Vinor Zukhubaia Co-Founder | Series B | 10 patents Patents concentrated in computing, sensing & instrumentation | — |
| 4 | Lamellar Develops patented medical devices and pharmaceuticals based on mimetics of extra-alveolar lamellar bodies | $18M | 112 mo ago | 11 | — | Series C | — | — |
| 5 | Bsolve Dental Developer of dissolvable dental and oral strips | $10M | 94 mo ago | 37 | — | Series A | — | — |
| 6 | Dxcover AI-powered device for earlier diagnosis of brain tumors | $9M | 19 mo ago | 16 16 → 31 (+94%) | Holly Butler Co-Founder & Chief Technical Officer | Series A | 32 patents Early cancer detection via spectroscopic analysis of biological samples and fluid diagnostics. | — |
| 7 | Nebu~Flow Developer of aerosol delivery platform technology | $8M | 28 mo ago | 11 | Julien Reboud Co-Founder | Series A | — | — |
| 8 | Aurum Biosciences A biopharmaceutical company developing novel oxygen carriers and proprietary software for use with MRI… | $6M | 31 mo ago | 6 | — | Series A | 8 patents Metabolic function diagnostics and imaging technologies for assessing cellular metabolism | — |
| 9 | Glox Theraputics Developer of precision antibiotics to target antimicrobial resistant pathogens | $5M | 21 mo ago | — | Colin Kleanthous Co-Founder | Seed | — | 1 award |
| 10 | Microplate Dx Developer of a diagnostic test for drug-resistant infections | $4M | 12 mo ago | 12 | Paul Hoskisson Co-Founder | Seed | 4 patents Microplate-based detection and analysis of microbial growth for diagnostic applications. | — |
| 11 | Nami Surgical Provider of ultrasonic scalpels for robotic-assisted surgery | $3M | 7 mo ago | — | Rebecca Cleary Co-Founder & CTO | Series A | 7 patents Ultrasonic surgical transducers for tissue cutting and coagulation in minimally invasive procedures | — |
| 12 | Taragenyx Regenerating skeletal implant design to help patients heal faster with far less pain. | $3M | 133 mo ago | — | Iain Mcdougall CEO | Deadpooled | 10 patents Advanced coating technologies for metal bone‑repair implants and related medical devices | — |
| 13 | Neuranics Developer of magnetic sensing technology for next-generation wearable systems 21Talent top 38%Growth top 45%Moat top 47%Funding bottom 47% All 10 signals ▾Talenttop 38% Growthtop 45% Moattop 47% Fundingbottom 47% Patentsbottom 41% Globalbottom 40% Innovationbottom 31% Techbottom 31% Marketbottom 27% Newsbottom 21% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Growth: Web rank 10,000,000 → 50,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 21/100 | $2M | 17 mo ago | 10 | Hadi Heidari Co-Founder & CTO | Seed | 2 patents Continuous cardiac arrhythmia monitoring using wearable sensor systems | — |
| 14 | Biomage Provider of a cloud-based cell and genomic sequence analysis platform for researchers | $2M | 68 mo ago | 6 | Adam Kurkiewicz CEO | Acquired | — | — |
| 15 | BioClavis Developer of a transcriptomic/genomic platform for precision diagnostics | $1M | 63 mo ago | 14 | Joel McComb CEO | Funding Raised | — | — |
| 16 | Clear Surgical Forceps and retractors for orthopaedic surgeons | $368K | 70 mo ago | 5 | — | Seed | 11 patents Illuminated surgical retractors and integrated guide devices for minimally invasive procedures. | — |
Top 12 Life Sciences companies in Glasgow
#1
Series B · Glasgow, Scotland · founded 2020 · 40 employees$43Mraised▾
Developer of a platform for digitizing chemistry and chemical discovery. The platform combines chemistry, robotics, computation, machine learning, and a programming language to automate molecule creation. It aims to accelerate molecular discovery and bridge the gap between design and synthesis. The company focuses on developing novel compounds and materials.
- Feb 2026Series B—
- Dec 2025Grant (prize money)$1.6M
- Oct 2025Series B$50M
- Oct 2024Grant (prize money)—
#2
Series A · Glasgow, Scotland · founded 2021$3.1Mraised▾
Provider of ultrasonic scalpels for robotic-assisted surgery. The company develops high-performance miniaturised ultrasonic scalpels for Robotic Assisted Surgery widely used in various surgical procedures such as urology, gynaecology, and cardiology.
- Jan 2026Series A$2.6M
- Aug 2025Series A$10M
- May 2024Seed$3.1M
- May 2024Grant (prize money)$877.5K
#3
Seed · Glasgow, Scotland · founded 2017 · 12 employees$3.7Mraised▾
Developer of a diagnostic test for drug-resistant infections. It offers a Rplate platform that combines hardware with data processing algorithms to perform rapid antibiotic susceptibility tests for urinary tract infections.
- Sep 2025Conventional Debt—
- Sep 2025Seed$644.6K
- Sep 2023Seed$3.1M
- Dec 2022Seed$610.2K
#4
Series A · Glasgow, Scotland · founded 2016 · 16 employees$9.2Mraised▾
AI-powered device for earlier diagnosis of brain tumors. The company's platform combines novel hardware with AI algorithms to develop Dxcover to analyze blood and detect the commonly occurring cancers.
- Feb 2025Series A$6.2M
- 2023Grant (prize money)$2.8M
- Feb 2023Series A$9.2M
- Dec 2022Grant (prize money)$2.7M
#5
Seed · Glasgow, Scotland · founded 2021 · 10 employees$2.3Mraised▾
Developer of magnetic sensing technology for next-generation wearable systems. The company uses magnetic sensing technology has potential applications in healthcare and can detect the magnetic fields generated by the muscles and the heart.
- Apr 2025Seed$8M
- Sep 2023Seed$2.3M
#6
Seed · Glasgow, Scotland · founded 2023$5.3Mraised▾
Developer of precision antibiotics to target antimicrobial resistant pathogens. The company has Glox discovery platform developing precision antibiotics to target drug-resistant Gram-negative pathogenic bacteria associated with serious infections and high antimicrobial resistance (AMR) and mortality.
- Nov 2024Grant (prize money)$1.3M
- Nov 2023Seed$5.3M
#7
Series A · Glasgow, Scotland · founded 2015 · 12 employees$44.5Mraised▾
Mironid was spun out of the University of Strathclyde in 2015. The company develops proprietary drug candidate molecules, by modulating the activity of key cell signaling enzymes such as phosphodiesterase 4 (PDE4) enzymes. The compnany is using physiology mirroring approach to discover drugs targeting key cell signaling enzymes. The company's initial focus is on major chronic inflammatory disease, degenerative kidney disease, and cancer.
- Sep 2023Series A$38.3M
- Jun 2016Series A$6.2M
#8
Series A · Glasgow, Scotland · founded 2019 · 11 employees$8Mraised▾
Developer of aerosol delivery platform technology
- Apr 2024Series A$5.9M
- Aug 2022Grant (prize money)$1.2M
- May 2022Seed$2.1M
#9
Series A · Glasgow, Scotland · founded 2015 · 6 employees$6.3Mraised▾
Aurum Biosciences Ltd is a biopharmaceutical company developing novel oxygen carriers and proprietary software for use with MRI, initially for Acute Ischaemic Stroke (AIS) and follow-on indications. Aurum Biosciences is using Oxycyte, an injectable perfluorocarbon (PFC) based oxygen carrier, to develop their proprietary Glasgow Oxygen Level Dependent (GOLD) technology. The company is currently taking a stroke management product (“GOLD”) through preclinical development and into clinical studies of efficacy and safety. GOLD is being developed as both a diagnostic (a combination of MRI Imaging, the Oxycyte and their proprietary software) and a therapeutic.
- Jan 2024Series A$926.3K
- Oct 2020Seed$873.9K
- Sep 2015Seed$4.5M
#10
Series B · Glasgow, Scotland · founded 2006 · 110 employees$30.7Mraised▾
Developer of light-sheet microscopy systems for multiple business verticals. It offers products for neuroscience, developmental biology, cancer biology, regenerative medicine, and other biosciences verticals. Its product range includes low-end IR to the high-end IR spectrum. They were awarded the IOP innovation award in 2015. Applications range from optical metrology to non-destructive testing.
- Nov 2020Conventional Debt$26.6M
- Nov 2020Series B$16.6M
- Oct 2020Grant (prize money)$720.9K
- Jan 2020Grant (prize money)$1.2M
#11
Series C · Glasgow, Scotland · founded 2007 · 11 employees$18.4Mraised▾
Lamellar Biomedical provides its proprietary Lamellasome™ technology which are mimetics of native extra-alveolar lamellar bodies. They work on developing the Class 3 medical devices, Visco-ease for Radiotherapy-Induced Xerostomia (RIX) and Lamell-eye for moderate to severe Dry Eye Disease (DED). It’s lead compound, LMS-611, is also being developed as a novel therapy for Cystic Fibrosis and has EU Orphan Drug status for this indication.
- May 2017Series C$7.5M
- Jul 2015Series B$3.6M
- Jan 2013Series A$5.3M
- Sep 2007Seed$2M
#12
Series A · Glasgow, Scotland · founded 2003 · 37 employees$10.1Mraised▾
Developer of dissolvable dental and oral strips. The company's dissolving films include Be Brighter used for teeth whitening, Be Soothed used to treat mouth ulcer patches, Be Fresher used for breath freshening, and Be Hydrated used for dry mouth.
- Nov 2018Series A$3.2M
- Apr 2014Series A$1M
- May 2013Series A$687.7K
- Oct 2011Series A$1.9M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Glasgow researches in biotechnology
- University of Glasgow21
- Glasgow Caledonian University2
- MRC University of Glasgow Centre for Virus Research2
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.